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Abstract Introduction Although guideline-adherent antithrombotic therapy (ATT) for stroke
prevention in atrial fibrillation (AF) is associated with lower mortality and thromboembo-
lism, ATTuptake shows geographic variation worldwide. We aimed to assess thromboem-
bolic risk and baseline ATT by geographic region and identify factors associated with
prescription of ATT in a large, truly global registry of patients with recently diagnosed AF.
Methods and Results Our analysis comprises 15,092 patients newly diagnosed with
non-valvular AF at risk for stroke, enrolled in Phase II of Global Registry on Long-Term
Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF). Global
oral anticoagulation (OAC) use was 79.9%, being highest in Europe (90.1%), followed by
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Introduction
Atrial fibrillation (AF) increases the risk of stroke and all-
cause mortality.1–3 Oral anticoagulation (OAC) with vitamin
K antagonists (VKAs) such as warfarin reduces stroke risk by
64% and mortality by 26%, compared with placebo/control,
while aspirin decreases stroke risk by an estimated 19% and
has no discernible effect on mortality.4 More recent clinical
trials have demonstrated that non-vitamin K antagonist
OACs (NOACs) are at least as effective as warfarin in stroke
prevention and may offer greater safety and convenience.5–9
After identification of ‘low-risk’ patients (congestiveheart
failure, hypertension, age  75 years [doubled], diabetes,
stroke/transient ischaemic attack (TIA)/thromboembolism
[doubled], vascular disease [prior myocardial infarction,
peripheral arterial disease or aortic plaque], age 65–74 years,
sex category [female] [CHA2DS2-VASc] score 0 in males, 1 in
females) who do not need any antithrombotic therapy,
stroke prevention with OAC should generally be considered
in patients with 1 stroke risk factors, given the positive net
clinical benefit when balancing reduced stroke risk against
the risk of major bleeding.10 However, substantial geo-
graphic differences in use of antithrombotic therapy have
been reported,11–13 and these differences almost certainly
affect thromboembolic and mortality rates.14–16
TheGlobal Registryon Long-TermOral Antithrombotic Treat-
ment inPatientswithAtrialFibrillation(GLORIA-AF) isoneof the
largest ongoing, international AF registries, which aims to assess
safety, effectiveness and utilization patterns of antithrombotic
therapy.17 The primary objective of this article is to explore
regional differences in thromboembolic risk and treatment
strategies in 15,092 AF patients from phase II of the registry.
We also examined the magnitude of influence of baseline
variables in regard to antithrombotic treatment choice.
Methods
Study Design
Details of GLORIA-AF study design have been previously
published.17 In brief, GLORIA-AF is a prospective registry of
patients with newly diagnosed AF at risk for stroke. The
registry consists of three overlapping phases: phase I was
the period before NOAC introduction, phase II began immedi-
ately following approval of the first NOAC in a given country
and phase III started once propensity score comparisons
indicated a substantial overlap in the range of the scores for
those receiving dabigatran and those receiving VKA, to facil-
itate a valid assessment of safety and effectiveness. This report
analyses baseline, cross-sectional data coming from patients
enrolled in phase II of the registry (between November 2011
and December 2014).
Patients and Settings
The registry aims to enrol up to 56,000 AF patients fromnearly
50 countries worldwide, from five geographical regions: (1)
Asia, (2) Europe, (3) North America, (4) Latin America and (5)
Africa/Middle East (►Fig. 1). The programme includes up to
2,200 sites in a variety of in- and outpatient settings, and
involves various medical specialties. Inclusion criteria were
as follows: adult patients, new onset (<3 months before
study entry, with the exception Latin America, where it was
<4.5 months due to referral patterns) non-valvular AF, and
1 risk factor for stroke as per the CHA2DS2VASc score. Main
exclusion criteria were as follows: mechanical heart valves or
valve disease requiring surgical valve replacement, history of
OAC with VKA less than 60 days for any indication, generally
reversible cause of AF, an indication other than AF for VKA
treatment and life expectancy less than 1 year.
Thromboembolic risk was assessed with the use of
CHA2DS2-VASc score.18 ‘Low-risk’ patients were defined as
CHA2DS2-VASc ¼ 1 in females (males with CHA2DS2-VASc
¼ 0 were not included); ‘moderate-risk’ patients as males
with CHA2DS2-VASc ¼ 1; and ‘high-risk’ patients as those
with CHA2DS2-VASc score 2. Bleeding risk assessment was
based on the HAS-BLED (hypertension, abnormal renal and
liver function, stroke, bleeding, labile INR [international
normalized ratio] values, age  65 years, drugs or alcohol)
score, and high-risk was defined as HAS-BLED  3.19
Data Collection
AnElectronicDataCapture System(Cambridge,Massachusetts,
United States) was used to collect and store data as well as to
ensure safety and confidentiality. High level of data integrity is
ensured by in-person monitoring, bimonthly calls to all sites
Africa/Middle East (87.4%) and Latin America (85.3%), North America (78.3%) and Asia
(55.2%). Among OAC users, vitamin K antagonists (VKAs) have been replaced by non-
VKA OACs (NOACs) as the more prevalent OAC option in all regions, with highest use in
North America (66.5%) and lowest in Asia (50.2%). In Asia, OAC was 80.4% in
community hospitals but only 49.8% in university hospitals and 42.6% in specialist
offices, and varied from 21.0% in China to 89.7% in Japan (NOACs at 5.8% in China and
83.3% in Japan). Globally, 76.5% of low-risk patients were prescribed ATT (46.1% OAC),
whereas 17.7% high-risk patients were not anticoagulated (Europe 8.8%; North America
18.9%; Asia 42.4%).
Conclusion Substantial inter- and intra-regional differences in ATT for stroke preven-
tion in AF are evident in this global registry. While guideline-adherent ATT can be
further improved, NOACs are the main contributor to high OAC use worldwide.
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to review data quality, entry and open queries, biweekly
updates of follow-up on data trends (e.g., missing data, termi-
nation rates, overdue forms, vital status), regular visits by audit
teams as well as quarterly medical review meetings to assess
aggregate data. Local investigators were instructed in detail
regarding system requirements and functionality as well
as encouraged to enrol consecutive eligible AF patients. All
patients entered the studyafterwritten, informedconsent, and
the study complies with the Declaration of Helsinki.
Statistical Analysis
Baseline datawere summarized descriptively. Continuous vari-
ables were reported as median and quartiles. Categorical vari-
ables were reported as absolute frequencies and percentages.
Logistic regression provides odds ratios (OR), which only
closely approximate risk ratios (i.e., relative risks) for rare
outcomes (<10%). Because use of OAC and NOAC was pre-
valent, we used log-binomial regression to estimate the risk
ratios directly.20Fromhere onand throughout the text,wewill
use the term ‘probability ratio’ rather than ‘risk ratio’ as our
measure describes drug use rather than adverse outcomes.
Both univariate and multivariable log-binomial regres-
sion analyses were conducted to, respectively, evaluate the
crude and adjusted probability ratios (together with 95%
confidence intervals [CIs]) of OAC among all eligible patients,
and of NOAC treatment among patients receiving OAC,
associated with the variables of clinical relevance: age,
gender, type of AF, categorization of AF, AF cardioversion,
hypertension, diabetes mellitus, previous stroke/TIA, con-
gestive heart failure, coronary artery disease, myocardial
infarction, peripheral artery disease, previous bleeding
events, chronic kidney disease, alcohol abuse, cancer, chronic
gastrointestinal disease, CHADS2 score, CHA2DS2-VASc score,
HAS-BLED score, geographic region, type of site and medical
treatment reimbursement. No variable selection procedure
was applied in the multivariable analyses. The COPYmethod
was used to obtain approximate maximum likelihood esti-
mateswhere the log-binomialmodel does not converge.21All
analyses were performed using SAS statistical software
version 9.4 (SAS Institute, Inc., Cary, North Carolina, United
States). Refer to online supplementary materials for more
details on methodology and statistical analysis.
Results
Baseline Data
Baseline characteristics by regionare summarized in►Table 1.
Patients from Asia were younger, with 28.5% being75 years,
comparedwithEurope (44.2%) andNorthAmerica (39.6%). The
most prevalent comorbidities were hypertension (varying
Fig. 1 Definition of geographical regions and country participation in Global Registry on Long-Term Oral Antithrombotic Treatment in Patients
with Atrial Fibrillation (GLORIA-AF).
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Table 1 Baseline characteristics by region




Asia, n ¼ 3,071
(20.3%)
Region 2




n ¼ 3,403 (22.5%)
Region 4
Latin America,
n ¼ 913 (6.0%)
Region 5
Africa/Middle East,
n ¼ 597 (4.0%)
Patient characteristics
Age, y, median [Q1,Q3] 71.0 [64–78] 68.0 [60–76] 73.0 [66–79] 71.0 [64–79] 71.0 [62–78] 70.0 [61–76]
Age, 75 y 5,907 (39.1) 874 (28.5) 3,144 (44.2) 1,349 (39.6) 354 (38.8) 186 (31.2)
Female gender 6,872 (45.5) 1,337 (43.5) 3,317 (46.7) 1,524 (44.8) 410 (44.9) 284 (47.6)
GFR, mL/min/1.73 m2, median [Q1,Q3] 75.1 [61–90] 78.7 [65–96] 74.0 [61–88] 74.3 [59–89] 72.5 [59–87] 75.2 [58–92]
No reimbursement for medications 1,076 (7.1) 375 (12.2) 313 (4.4) 103 (3.0) 183 (20.0) 102 (17.1)
Medical history
Hypertension 11,255 (74.6) 2,130 (69.4) 5,217 (73.4) 2,738 (80.5) 690 (75.6) 480 (80.4)
Hyperlipidaemia 6,026 (39.9) 821 (26.7) 2,595 (36.5) 2,085 (61.3) 246 (26.9) 279 (46.7)
Diabetes mellitus 3,487 (23.1) 619 (20.2) 1,510 (21.2) 921 (27.1) 185 (20.3) 252 (42.2)
Previous stroke/TIA 2,147 (14.2) 400 (13.0) 1,107 (15.6) 422 (12.4) 110 (12.0) 108 (18.1)
Congestive heart failure 3,647 (24.2) 837 (27.3) 1,662 (23.4) 671 (19.7) 296 (32.4) 181 (30.3)
Coronary artery disease 3,068 (20.3) 674 (21.9) 1,167 (16.4) 919 (27.0) 114 (12.5) 194 (32.5)
Myocardial infarction 1,600 (10.6) 246 (8.0) 741 (10.4) 418 (12.3) 96 (10.5) 99 (16.6)
Abnormal kidney functiona 241 (1.6) 45 (1.5) 89 (1.3) 75 (2.2) 12 (1.3) 20 (3.4)
Type of AF
Paroxysmal 8,052 (53.4) 1,804 (58.7) 3,326 (46.8) 2,240 (65.8) 396 (43.4) 286 (47.9)
Persistent 5,362 (35.5) 1,086 (35.4) 2,763 (38.9) 1,007 (29.6) 316 (34.6) 190 (31.8)
Permanent 1,678 (11.1) 181 (5.9) 1,019 (14.3) 156 (4.6) 201 (22.0) 121 (20.3)
Categorization of AF
Symptomatic 4,263 (28.2) 751 (24.5) 2,258 (31.8) 804 (23.6) 292 (32.0) 158 (26.5)
Minimally symptomatic 6,004 (39.8) 1,460 (47.5) 2,671 (37.6) 1,278 (37.6) 323 (35.4) 272 (45.6)
Asymptomatic 4,825 (32.0) 860 (28.0) 2,179 (30.7) 1,321 (38.8) 298 (32.6) 167 (28.0)
Interventions in AF
AF cardioversion 2,431 (16.1) 331 (10.8) 1,226 (17.2) 646 (19.0) 143 (15.7) 85 (14.2)
AF ablation 161 (1.1) 93 (3.0) 33 (0.5) 26 (0.8) 5 (0.5) 4 (0.7)
CHA2DS2-VASc 3.0 3.0 3.0 3.0 3.0 3.0
Low risk (score 1 in women) 332 (2.2) 110 (3.6) 114 (1.6) 83 (2.4) 14 (1.5) 11 (1.8)
Moderate risk (score 1 in men) 1,761 (11.7) 532 (17.3) 684 (9.6) 387 (11.4) 108 (11.8) 50 (8.4)
High risk (score 2) 12,999 (86.1) 2,429 (79.1) 6,310 (88.8) 2,933 (86.2) 791 (86.6) 536 (89.8)
HAS-BLED 1.0 1.0 1.0 1.0 1.0 1.0
Low risk (score 0–2) 11,927 (79.0) 2,359 (76.8) 5,538 (77.9) 2,775 (81.5) 772 (84.6) 483 (80.9)
High risk (score 3) 1,376 (9.1) 329 (10.7) 575 (8.1) 352 (10.3) 59 (6.5) 61 (10.2)
Missing 1,789 (11.9) 383 (12.5) 995 (14.0) 276 (8.1) 82 (9.0) 53 (8.9)
Physician specialty
Cardiologist 13,863 (91.9) 2,994 (97.5) 6,568 (92.4) 2,872 (84.4) 864 (94.6) 565 (94.6)
GP/geriatrician 359 (2.4) 34 (1.1) 63 (0.9) 229 (6.7) 32 (3.5) 1 (0.2)
Internist 322 (2.1) 12 (0.4) 71 (1.0) 197 (5.8) 17 (1.9) 25 (4.2)
Neurologist 147 (1.0) 7 (0.2) 63 (0.9) 77 (2.3) 0 (0.0) 0 (0.0)
Other 386 (2.6) 24 (0.8) 328 (4.6) 28 (0.8) 0 (0.0) 6 (1.0)
Missing 15 (0.1) 0 (0.0) 15 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Type of setting
GP/primary care 968 (6.4) 178 (5.8) 216 (3.0) 496 (14.6) 75 (8.2) 3 (0.5)
Specialist office 4,567 (30.3) 611 (19.9) 1,200 (16.9) 2,290 (67.3) 320 (35.0) 146 (24.5)
Community hospital 3,969 (26.3) 561 (18.3) 2,717 (38.2) 298 (8.8) 251 (27.5) 142 (23.8)
University hospital 5,081 (33.7) 1,659 (54.0) 2,715 (38.2) 265 (7.8) 207 (22.7) 235 (39.4)
Outpatient/anticoagulation clinic 381 (2.5) 62 (2.0) 143 (2.0) 54 (1.6) 51 (5.6) 71 (11.9)
Other 126 (0.8) 0 (0.0) 117 (1.6) 0 (0.0) 9 (1.0) 0 (0.0)
Abbreviations: AF, atrial fibrillation; CHA2DS2-VASc, congestive heart failure, hypertension, age 75 years (doubled), diabetes, stroke/transient
ischaemic attack/thromboembolism (doubled), vascular disease (prior myocardial infarction [MI], peripheral arterial disease [PAD] or aortic plaque),
age 65 to 74 years, sex category (female); GFR, glomerular filtration rate; GP, general practitioner; HAS-BLED, hypertension, abnormal renal and liver
function, stroke, bleeding, labile INR (international normalized ratio), age 65 years, drugs or alcohol; TIA, transient ischaemic attack.
aDefined as the presence of chronic dialysis or renal transplantation or serum creatinine 200 μmol/L.
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from 80.5% in North America to 69.4% in Asia) and hyperlipi-
daemia (61.3% in North America, 26.7% in Asia). Diabetes was
most common in Africa/Middle East (42.2%) and less frequent
in Asia (20.2%). The proportion of secondary prevention
patients (withprior stroke/TIA), aswell as thosewith coronary
artery disease andpreviousmyocardial infarction,washighest
in Africa/Middle East (18.1, 32.5 and 16.6%, respectively).
Congestive heart failure was most common in Latin America
(32.4%) and lowest in North America (19.7%).
The vast majority of patientswere treated by cardiologists
(91.9%), with some differences among regions (97.5% in Asia
and 84.4% in North America). In Asia, 54% of patients were
enrolled in university hospitals, while inNorth Americamost
of the subjects were recruited in specialist offices (67.3%).
Overall, 79.9% of all patients were prescribed OAC: 32.3%
VKA and 47.6% NOACs (dabigatran 31.6%, rivaroxaban 11.4%
and apixaban 4.6%), while 12.1% received antiplatelet drugs
(aspirin in 93.1% of cases) and 7.8% received no antithrom-
botic therapy. Of those at low bleeding risk, 81.8% were
anticoagulated, 9.6% received aspirin, 0.6% other antithrom-
botic drugs and 8.1% were not treated. The corresponding
proportions for those at high riskof bleeding (HAS-BLED 3)
were 63.4, 27.6, 3.6 and 5.3%.
Antithrombotic Therapy by Region
The highest OAC rates were observed in Europe (90.1%),
followed by Africa/Middle East (87.4%), Latin America
(85.3%) and North America (78.3%), while in Asia it was
55.2% (►Fig. 2A). In the subgroup of patients on OACs
(n ¼ 12,065; 79.9%), the most prevalent option was NOACs
in North America (66.5%), Latin America (66.0%) and Africa/
Middle East (63.6%; ►Fig. 2B). In Asia, the probability that a
patient with AF remained untreatedwas the highest, at 19.8%,
and in the Africa/Middle East region, it was the lowest, at 1.5%.
Antiplatelet therapy was common in Asia (25.0%) and least
prevalent in Europe (6.0%; ►Fig. 2A).
Antithrombotic Therapy by Region and Stroke Risk
In Europe, 64.9% of low-risk patients were prescribed OAC and
14.9% antiplatelets. In North America, the corresponding num-
bers were 39.8 and 49.4%, respectively, while in Asia, 28.2 and
32.7%, respectively (►Fig. 3). Among European patients at
moderate risk of stroke, 85.1% received OAC, compared with
79.6% in Latin America and 74.0% in Africa/Middle East. Corre-
sponding proportions inNorthAmerica andAsiawere67.7 and
49.4%, respectively. In high-risk patients, OAC use was highest
inEurope (91.1%), followedbyAfrica/Middle East (89.2%), Latin
America (86.6%), North America (80.8%) and Asia (57.6%).
Antithrombotic Therapy by Region and Country
►Table 2 summarizes enrolment rate by regions and countries
with their respective antithrombotic treatment patterns.
Europe was the highest recruiting region with 7,108 patients
(47.1%)enrolled,whereasUnitedStateswas thehighest recruit-
ing country (n ¼ 3,007; 19.9%). The greatest heterogeneity in
OAC prescription was noted in Asia, where anticoagulation
varied from 21.0% in China to 89.7% in Japan. For Europe,
generally high overall OAC rateswere observed in all countries,
and with the exception of only a few high-enrolling countries
(>500 patients enrolled, i.e., the Netherlands, Spain, United
Kingdom), NOACs were the more prevalent OAC option.
Antithrombotic Therapy by Region and Clinical Setting
In Asia, 80.4% of patients from community hospitals were
anticoagulated, compared with 49.8 and 42.6% of those from
university hospitals and specialist offices, respectively
(►Fig. 4). NOACs and VKAs were prescribed for 71.1 and
9.3% of patients from community hospitals; in university
hospitals, the corresponding numbers were 11.0 and 38.8%,
and in specialist offices, 21.6 and 20.9%, respectively.
Overall, physicians from university hospitals prescribed
more VKAs (42.7%) and less NOACs (33.0%). In North America,
the highest anticoagulation use was reported by university
Fig. 2 Antithrombotic treatments by region, overall (A) and among oral anticoagulant (OAC) users (B). Other antithrombotic therapy includes
the combination of antithrombotic agents.
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hospitals at 83.0% (53.6% NOACs and 29.4% VKAs), compared
with 69.8% in community hospitals and 70.6% in general
practices. The highest prevalence of aspirin treatment or
non-treatment was seen not only in Asian specialist offices
(55.8%) and university hospitals (48.5%), but also in American
community hospitals (29.5%) and general practices (29.0%).
Anticoagulation Therapy versus Other Treatment
A log-binomial regression analysis for estimation of prob-
ability ratios for the prescription of anticoagulation
therapy (VKA, NOAC) versus other treatment (antiplatelet
or no treatment) is presented in ►Supplementary Table S1
(online only). In the multivariable analysis, adjusted
Fig. 3 Antithrombotic treatment by region and stroke risk.a Other ¼ antiplatelets other than acetylsalicylic acid (ASA) and combination of
antithrombotic agents; Xa inhibitor ¼ rivaroxaban, apixaban. aIn Latin America and Africa/Middle East, score ¼ 1 in females is not shown as
there were too low patient numbers to calculate meaningful percentages for comparison.
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Asia 3,071 (100) 608 (19.8) 727 (23.7) 844 (27.5) 850 (27.7) 1,694 (55.2) 42 (1.4)
China 1,018 (33.1) 431 (42.3) 351 (34.5) 155 (15.2) 59 (5.8) 214 (21.0) 22 (2.2)
Hong Kong 49 (1.6) 3 (6.1) 13 (26.5) 9 (18.4) 24 (49.0) 33 (67.3) 0
Japan 312 (10.2) 27 (8.7) 5 (1.6) 20 (6.4) 260 (83.3) 280 (89.7) 0
Russian Federation 404 (13.2) 2 (0.5) 45 (11.1) 75 (18.6) 282 (69.8) 357 (88.4) 0
Singapore 48 (1.6) 5 (10.4) 5 (10.4) 23 (47.9) 14 (29.2) 37 (77.1) 1 (2.1)
South Korea 997 (32.5) 117 (11.7) 282 (28.3) 541 (54.3) 42 (4.2) 583 (58.5) 15 (1.5)
Taiwan 243 (7.9) 23 (9.5) 26 (10.7) 21 (8.6) 169 (69.5) 190 (78.2) 4 (1.6)
Europe 7,108 (100) 272 (3.8) 373 (5.2) 2,687 (37.8) 3,717 (52.3) 6,404 (90.1) 59 (0.8)
Austria 62 (0.9) 1 (1.6) 0 5 (8.1) 56 (90.3) 61 (98.4) 0
Belgium 38 (0.5) 4 (10.5) 2 (5.3) 3 (8.0) 29 (76.3) 32 (84.2) 0
Bulgaria 303 (4.3) 3 (1.0) 6 (2.0) 61 (20.1) 233 (76.9) 294 (97.0) 0
Croatia 165 (2.3) 11 (6.7) 36 (21.8) 96 (58.2) 22 (13.3) 118 (71.5) 0
Czech Republic 75 (1.1) 7 (9.3) 3 (4.0) 53 (70.7) 12 (16.0) 65 (86.7) 0
Denmark 62 (0.9) 2 (3.2) 0 14 (22.6) 46 (74.2) 60 (96.8) 0
Estonia 45 (0.6) 0 0 17 (37.8) 28 (62.2) 45 (100) 0
France 969 (13.6) 21 (2.2) 22 (2.3) 195 (20.1) 729 (75.2) 924 (95.4) 2 (0.2)
Germany 1,220 (17.2) 39 (3.2) 75 (6.1) 201 (16.5) 899 (73.7) 1,100 (90.2) 6 (0.5)
Greece 270 (3.8) 7 (2.6) 9 (3.3) 113 (41.9) 141 (52.2) 254 (94.1) 0
Republic of Ireland 61 (0.9) 1 (1.6) 5 (8.2) 13 (21.3) 42 (68.9) 55 (90.2) 0
Italy 359 (5.1) 17 (4.7) 14 (3.9) 111 (30.9) 214 (59.6) 325 (90.5) 3 (0.8)
Latvia 60 (0.8) 0 20 (33.3) 6 (10.0) 34 (56.7) 40 (66.7) 0
The Netherlands 528 (7.4) 9 (1.7) 12 (2.3) 317 (60.0) 188 (35.6) 505 (95.6) 2 (0.4)
Norway 77 (1.1) 2 (2.6) 2 (2.6) 16 (20.8) 57 (74.0) 73 (94.8) 0
Poland 75 (1.1) 4 (5.3) 3 (4.0) 9 (12.0) 59 (78.7) 68 (90.7) 0
Portugal 164 (2.3) 5 (3.0) 3 (1.8) 56 (34.1) 100 (61.0) 156 (95.1) 0
Romania 301 (4.2) 1 (0.3) 17 (5.6) 121 (40.2) 152 (50.5) 273 (90.7) 10 (3.3)
Slovenia 68 (1.0) 0 0 2 (2.9) 66 (97.1) 68 (100) 0
Spain 1,155 (16.2) 78 (6.8) 70 (6.1) 725 (62.8) 273 (23.6) 998 (86.4) 9 (0.8)
Sweden 137 (1.9) 0 0 80 (58.4) 57 (41.6) 137 (100) 0
Switzerland 72 (1.0) 1 (1.4) 3 (4.2) 20 (27.8) 47 (65.3) 67 (93.1) 1 (1.4)
United Kingdom 842 (11.8) 59 (7.0) 71 (8.4) 453 (53.8) 233 (27.7) 686 (81.5) 26 (3.1)
North America 3,403 (100.0) 255 (7.5) 455 (13.4) 892 (26.2) 1,774 (52.1) 2,666 (78.3) 27 (0.8)
Canada 396 (11.6) 8 (2.0) 47 (11.7) 101 (25.5) 238 (60.1) 339 (85.6) 2 (0.5)
United States 3,007 (88.4) 247 (8.2) 408 (13.6) 791 (26.3) 1,536 (51.1) 2,327 (77.4) 25 (0.8)
Latin America 913 (100.0) 38 (4.2) 92 (10.1) 265 (29.0) 514 (56.3) 779 (85.3) 4 (0.4)
Argentina 153 (16.8) 4 (2.6) 14 (9.2) 62 (40.5) 73 (47.7) 135 (88.2) 0
Brazil 306 (33.5) 28 (9.2) 42 (13.7) 99 (32.4) 137 (44.8) 236 (77.1) 0
Chile 11 (1.2) 0 1 (9.1) 7 (63.6) 3 (27.2) 10 (90.9) 0
Colombia 134 (14.7) 2 (1.5) 6 (4.5) 29 (21.6) 97 (72.4) 126 (94.0) 0
Ecuador 36 (4.0) 1 (2.8) 5 (13.9) 5 (13.9) 23 (63.9) 28 (77.8) 2 (5.6)
Mexico 220 (24.1) 1 (0.5) 21 (9.5) 47 (21.4) 149 (67.7) 196 (89.1) 2 (0.9)
Peru 44 (4.8) 1 (2.3) 2 (4.5) 15 (34.1) 26 (59.1) 41 (93.2) 0
Venezuela 9 (1.0) 1 (11.1) 1 (11.1) 1 (11.1) 6 (66.7) 7 (77.8) 0
Africa/Middle East 597 (100.0) 9 (1.5) 59 (9.9) 190 (31.8) 332 (55.6) 522 (87.4) 7 (1.2)
Lebanon 243 (40.7) 1 (0.4) 29 (11.9) 62 (25.5) 148 (60.9) 210 (86.4) 3 (1.2)
Saudi Arabia 235 (39.4) 4 (1.7) 8 (3.4) 77 (32.8) 145 (61.7) 222 (94.5) 1 (0.4)
Republic of South Africa 32 (5.4) 2 (6.3) 1 (3.1) 25 (78.1) 3 (9.4) 28 (87.5) 1 (3.1)
United Arab Emirates 87 (14.6) 2 (2.3) 21 (24.1) 26 (29.9) 36 (41.4) 62 (71.3) 2 (2.3)
Abbreviations: ASA, aspirin; NOAC, non-vitamin K antagonists oral anticoagulant; VKA, vitamin K antagonists; OAC, oral anticoagulant; Other,
antiplatelets other than aspirin and combination of antithrombotic agents.
Note: Data are presented as n (%)—row percentages.
aData presented in column percentages.
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probability ratios were calculated for OAC use versus other
therapy use.
A lower adjusted probability for OAC treatment pre-
scription compared with other therapy was found for
patients with low and moderate thromboembolic risk by
CHA2DS2-VASc score (probability 0.63 [95% CI: 0.55–0.71],
0.91 [95% CI: 0.88–0.94], respectively) and high bleeding
risk by HAS-BLED score (0.79 [95% CI: 0.76–0.82]) as well
as those recruited in regions of Asia, North and Latin
America (vs. Europe, probability ratios 0.66 [95% CI: 0.64–
0.69], 0.91 [95% CI: 0.89–0.93], 0.96 [95% CI: 0.94–0.99],
respectively).
Fig. 4 Antithrombotic treatment by region and setting.a Other ¼ antiplatelets other than acetylsalicylic acid (ASA) and combination of antithrombotic
agents. aIn Europe, n ¼ 117 (1.6%) and Latin America n ¼ 9 (1%) patients were included in other types of sites not shown in this graphic.
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Non–Vitamin K Antagonist versus Vitamin K
Antagonist
A log-binomial regression analysis for estimation of prob-
ability ratios for the prescription of NOAC versus VKA is
presented in ►Supplementary Table S2 (online only). In the
multivariable analysis, adjusted probability ratios were cal-
culated for NOAC (compared with VKA use).
Patients recruitedatspecialistoffice, communityhospital and
other health care settings, compared with university hospitals,
had ahigher adjustedprobability forNOACversusVKAprescrip-
tion, probability ratios 1.53 (95% CI: 1.46–1.60), 1.46 (95% CI:
1.39–1.53), 1.52 (95% CI: 1.43–1.60), respectively. In contrast,
patients with persistent AF (vs. paroxysmal AF, probability ratio
0.93 [95% CI: 0.90–0.96]), diabetes mellitus (probability ratio
0.92 [95% CI: 0.88–0.96]), prior myocardial infarction (probabil-
ity ratio 0.85 [95% CI: 0.80–0.91]) and chronic kidney disease
(probability ratio 0.92 [95% CI: 0.89–0.96]) had a lower prob-
ability for NOAC use, compared with VKA.
Discussion
The principal findings of this analysis are as follows: (1)
despite a relatively high global OAC use, substantial inter-
regional differences are evident, with OAC use being highest
in Europe (90.1%) and lowest in Asia (55.2%); (2) among OAC
users, NOACs have replaced VKAs as the more prevalent
option in all regions, with the highest uptakes in North
America (66.5%) and lowest in Asia (50.2%); (3) intra-regio-
nal differences in antithrombotic therapy use are apparent;
and (4) AF guideline adherence requires improvement, as
nearly half of low-risk patients are over-treated, while every
sixth high-risk patient (8.8% in Europe, 18.9% in North
America and 42.4% in Asia) is under-treated with OAC.
There may be several potential reasons for substantial
heterogeneity in OAC use by regions in this analysis, such as
apparent differences in baseline characteristics, associated
comorbid disease, thromboembolic and bleeding risk, type of
AForenrollingsite,physicians’specialty,AFguidelinesorhealth
care system and reimbursement in a given country.11–13,22–24
While someprevious reportshaveshown that thereare regions
with lower OAC uptake, particularly in Asia, we found that the
uptake within regions varies considerably by country, health
care setting and type of anticoagulation (VKA vs. NOACs).25–27
Prior studies have reported several issues limiting optimal
anticoagulation, such as fear of bleeding complications or poor
quality of INR control.27–29 Our study shows that NOACs are a
more prevalent treatment option than VKAs in all study
regions, and in 33 out of 44 participating countries. Even
more importantly, higher anticoagulation rateswere observed
in those regions and countries where NOACs were the main
anticoagulants. This was evident in Africa/Middle East and
Latin America, which as regions was found to be associated
with higher use of NOACs (vs. VKAs) compared with Europe,
and reported even higher anticoagulation uptake than North
America. Interestingly, in Africa/Middle East and Latin Amer-
ica, therewas no reimbursement formedications in 14 to 26%,
while self-pay for medications was only reported in approxi-
mately 3 to 4% in North America and Europe.
Despite having the highest NOAC uptake among OAC users,
overall anticoagulation use in North America was relatively
low. This pattern may be partially explained by American AF
guidelines, which in contrast to the European and Asia Pacific
guidelines offer OAC, aspirin or even no AF stroke prophylaxis
in patients with CHA2DS2-VASc score of 1, while OAC is
recommended in those with the score 2.30–32 When com-
paredwithother regionsofGLORIA-AFregistry, theproportion
of participating cardiologists in North America was lowest.
Indeed, lower prescription rates have been reported by regis-
tries where broader spectrum of physician specialties were
included.24 In addition, the incidence of paroxysmal AF (as
compared with other AF patterns) was also highest in North
America and in the present analysis,was associatedwith lower
OACprescription.Other studieshavealsoreported lessOACuse
in patients with paroxysmal AF, although current guidelines
recommend anticoagulation regardless of AF pattern.30,33
The highest overall OAC use was reported in Europe, with
generally NOACs beingmore frequently prescribed thanVKAs.
However in some countries, including high-enrolling ones (i.e.,
theNetherlands, Spain andUnitedKingdom), VKAsweremore
frequently prescribed than NOACs. Western European coun-
tries generally provide good quantity and quality of antic-
oagulation and more guideline-adherent OAC use compared
with other European and non-European countries.16,34,35
Regardless of OAC type (whether with anNOAC or VKA), being
treated for AF in Europewas associatedwith higher likelihood
of being anticoagulated (vs. antiplatelet or no therapy), com-
pared with North and Latin America or Asia.
Another important finding relates to health care clinical
settings. Overall physicians fromuniversity hospitals prescribed
anticoagulation less frequently than thosefromotherhealthcare
settings, and preferred VKAs over NOACs. Potential reasons for
such differences in treatment patterns by settingmay bemulti-
factorial and may include more common and complex invasive
procedures being performed or higher number of patients with
comorbid disease and contraindications to OAC being enrolled
by university hospitals. Nonetheless, a growing bodyof evidence
suggests that OAC should be neither interrupted nor bridged
during various invasiveprocedures, includingAFablation, as this
does not lower the risk of bleeding complications but brings
increased risk of thromboembolism.36–38
Geographic differences may also play a role. For example,
OAC prescription in Asian university hospitals was nearly
twofold lower than in community hospitals or specialist
offices, whereas in other regions a more homogenous dis-
tribution of OAC by setting (regardless of anticoagulant type)
was observed. Such heterogeneity in anticoagulation rates
between community and university hospitals in Asia may
reside in more evident between-country differences in na-
tional health care systems compared with other geographic
regions. In addition, country- and site-specific OAC prescrip-
tion patterns and predominantly enrolling sites may play a
role. Indeed, for example, 1 in 5 patients in China versus 9 in
10 in Japan were prescribed OAC. A marked difference in
NOAC versus VKA prescription was also noted, with overall
higher OACuse in those Asian countrieswhere NOACwas the
main anticoagulant.
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In Europe, nearly two-thirds of low-risk patients were
anticoagulated, while many patients with 2 stroke risk
factors are not treated as such.39,40 Also, aspirin is commonly
prescribed to low-risk patients and those at high risk of
bleeding, being prescribed in 10.0% of subjects at high throm-
boembolic risk. Strokepreventionwithaspirinmonotherapy is
neither effective nor safe, andmajority of AF guidelines do not
recommend its use.30,32,41 Such non-compliance with guide-
lines has been reportedbyprevious registries,which observed
improved outcomes in patients whowere treated in line with
AF guidelines.14,16
Limitations and Strengths
GLORIA-AF is not a population-based programme, which
limits patient representativeness. Particularly, relatively low
number of patients has been enrolled from Latin America and
Africa/Middle East. Patients could enter the study only after
signing an informed consent, which might have resulted in
higher anticoagulation rates compared with general AF popu-
lation. Inclusion of patients with new onset AF and once
NOACs were on offer in given countries could result in higher
OAC rates compared with registries which enroll AF ‘all-
comers’. As countries with various health care systems, drug
reimbursement policy, predominantly enrolling sites, AF
guidelines and different OAC prescribing patterns have been
groupedwithin one geographic region, a bias resulting from a
direct comparison of antithrombotic treatment among such
defined regions cannot be excluded. Because a considerable
number of countries did not enrol enough patients to allow
meaningful country-specific data, country (as a variable) was
not incorporated into themultivariable analysis. Higher use of
dabigatranversusotherNOACs shouldnot be surprising as this
report covers specifically the period that started once thefirst
NOAC (predominately dabigatran) became available in a given
country.17,42
Nevertheless, despite not being representative for the
general AF population, GLORIA-AF is as much representative
as other AF registries in the field, what is also reflected by
inclusion/exclusion criteria. Global reach, broad country, site
and physician inclusion, high-quality controlmeasures along
with unique study design with phase II commencing data
collection immediately following first NOAC launch in given
countries are evident strengths of GLORIA-AF. Consequently,
this report provides an up-to-date global, regional (conti-
nental) and local (including country and health care setting)
overview of contemporary antithrombotic treatment pat-
terns for stroke prevention in newly diagnosed AF.
Conclusion
Substantial inter- and intra-regional differences in ATT for
stroke prevention in AFare evident, as summarized in►Fig. 5.
While guideline-adherent ATT can be further improved,
NOACs are the main contributor to high OAC use worldwide.
Fig. 5 Summary infographic showing substantial inter- and intra-regional differences in antithrombotic therapy for stroke prevention in AF
(atrial fibrillation).
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